Recent Updates
Recently added Catalysts
STOK Positive Sentiment

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Monday, October 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Stoke Therapeutics has successfully completed a meeting with the FDA to discuss the planned New Drug Application (NDA) for zorevunersen, an investigational treatment for Dravet syndrome. This meeting aimed to align on critical aspects of the NDA process, marking a significant step forward for the company's lead product. Zorevunersen is positioned as a first-in-class therapy with the potential to modify the disease.

Market Sentiment Analysis

POSITIVE FACTORS

  • Successful meeting with the FDA
  • Alignment on key aspects for NDA
  • Potential disease-modifying treatment for Dravet syndrome

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+74%
120-day peak, hindsight
Typical move
3.5%
average across 5 past catalysts
Cash runway
~17 mo
Low dilution risk
Lead asset
STK-001- Single Ascending Doses
Phase 1 · Dravet Syndrome

Full Press Release Details

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced the completion of a successful meeting with the U.S. Food and Drug Administration (FDA) intended to align on key aspects of the

Frequently Asked Questions

What is zorevunersen?

Zorevunersen is an investigational medicine developed by Stoke Therapeutics for Dravet syndrome.

What was the outcome of the FDA meeting?

The meeting was successful and aimed to align on key aspects of the NDA for zorevunersen.

What is Dravet syndrome?

Dravet syndrome is a severe form of epilepsy that begins in infancy.

What is the significance of the NDA?

The NDA is a crucial step in the regulatory process for seeking approval to market zorevunersen.

ShareAdd on Google
Tags: STOK Stoke Therapeutics FDA meeting zorevunersen Dravet syndrome NDA
Last updated: Oct 5, 2026

Biotech snapshot

Cash runway
$354M liquidity · $19M/mo burn
~17 mo
Low dilution risk
Lead asset
STK-001- Single Ascending DosesPhase 1
Dravet Syndrome →

Catalyst track record

+74%
best trade around STOK's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for STOK.

See every catalyst's timing & PoA →